Lifileucel Ontario case: why it matters beyond melanoma
In September 2026, the Ontario Divisional Court quashed OHIP’s refusal to fund out-of-country treatment with lifileucel (Amtagvi) for a 37-year-old man with advanced metastatic melanoma and sent the decision back to the province for reconsideration.
Lifileucel is already approved by Health Canada, but reimbursement review and price negotiations are still underway. Ontario had argued, among other things, that funding the treatment outside Canada while negotiations were ongoing could affect its future negotiating position. The Court did not order Ontario to fund the treatment. Rather, it found that protecting the province’s negotiating position could not, on its own, be used as a blanket reason to deny an individual patient without considering the patient’s clinical circumstances, urgency, available alternatives and the potential impact on the health system.
The case has implications beyond melanoma, particularly for rare diseases and other conditions where treatments are intended for very small, highly selected patient populations.
Melanoma itself is not a rare disease. However, lifileucel is only intended for a much smaller group of patients: adults with unresectable or metastatic melanoma whose disease has progressed following PD-1 therapy and, where applicable, BRAF-targeted therapy. The FDA granted lifileucel orphan-drug designation for malignant melanoma stages IIb–IV in 2015. Its current U.S. indication is narrower and applies to the previously treated advanced population.
This raises an important question for rare disease policy: does rarity have to be defined by the disease itself, or can it also exist within a disease when only a very small number of patients are eligible for a particular treatment?
There is already some recognition of this concept in Canada’s Rare Disease Drug Strategy. Yescarta, a CAR-T therapy, is included on the federal-provincial Rare Disease Common List for follicular lymphoma and selected large B-cell lymphoma settings. The FDA designated Yescarta as an orphan drug for follicular lymphoma, including the approved population of adults with relapsed or refractory disease after at least two prior lines of therapy. Canada has also included Yescarta among the drugs supported through the Rare Disease Strategy Common List.
The parallel with the Alberta Casgevy case
A similar issue arose in Alberta with a patient with beta-thalassemia seeking treatment with Casgevy. The therapy was considered clinically appropriate, but Alberta did not want to fund domestic treatment while national price negotiations were still unresolved, given concerns about the impact on the negotiation process. The patient was instead approved for treatment in the United States.
These cases raise a broader policy issue. There can be situations where governments are prepared to pay for treatment outside Canada rather than establish domestic funding while price negotiations are ongoing. From a patient perspective, however, the location of treatment does not change the urgency of the clinical need.
The lifileucel decision is relevant because it challenges the idea that concerns about future price negotiations can, by themselves, determine whether an individual patient receives treatment. It does not remove the need for governments to negotiate sustainable prices. It does, however, highlight the tension between the time required for reimbursement processes and the clinical timelines faced by patients.
For someone with progressive cancer, thalassemia requiring definitive treatment, or another serious rare condition, waiting for HTA review, pCPA negotiations, contracting and implementation can have consequences that cannot simply be reversed once the process is complete.
Implications for Phase 2 of the Rare Disease Strategy
Taken together, lifileucel, Casgevy and Yescarta illustrate why Canada may need to think beyond disease prevalence when designing access pathways for very small treatment populations.
Regulatory approval, clinical eligibility, reimbursement negotiation, delivery readiness and actual patient access are separate steps. A patient can meet the clinical criteria for a treatment and still have no practical pathway to receive it.
This is not limited to diseases that are formally classified as rare. The same issue can arise when a treatment is intended for a small population defined by a particular disease subtype, stage, biomarker, previous treatment history or treatment failure, or when delivery requires highly specialized infrastructure.
One option for Phase 2 would be to recognize these small, clearly defined treatment populations alongside traditional rare disease definitions. This could include developing prospective bridge-access mechanisms for situations where:
· the treatment is authorized and considered clinically appropriate;
· the eligible population is small and clearly defined;
· delaying treatment creates a significant risk of death or irreversible deterioration;
· reimbursement or price negotiations are still underway; and
· the treatment cannot yet be routinely delivered in Canada.
The goal would not be to bypass the reimbursement system or interfere with price negotiations. Rather, it would be to avoid situations where patients and provinces are left to find ad hoc solutions, including litigation, exceptional-access requests or costly out-of-country treatment.
The broader lesson from these cases is that access challenges can arise even when a treatment is approved and a patient is clearly eligible. A small treatment population can create many of the same practical challenges as a rare disease, regardless of how common the underlying disease is. Phase 2 provides an opportunity to consider whether the strategy should account for these populations and create a clearer pathway from clinical eligibility to actual access.